Lexaria Bioscience Corp. (LEXX)
Data as of , from SEC Form 4 filings.
See up to 3 months of LEXX. The 7-day demo opens the 1M and 3M ranges and puts LEXX on your watchlist.
Start 7-day demoLatest LEXX insider trades
About Lexaria Bioscience Corp. (LEXX)
Lexaria Bioscience Corp. files with the SEC under CIK 0001348362 and is classified as pharmaceutical preparations. It is grouped with Health Care companies on this site. A registration statement was filed on 5 December 2025. No offering has priced.
LEXX Form 4 activity by transaction type, last 90 days
No Form 4 activity for LEXX in the last 90 days.
LEXX insider transactions (Form 4)
1210 Form 4 filings on record, the earliest from Dec 3, 2024, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Christopher Bunka - Director | Gift | common shares | 100,000 footnote F1 | $0.00 | - | |
| ||||||
| Christopher Bunka - Director | Open-market purchase | common shares | 15,600 | $0.92 | $14K | |
| Christopher Bunka - Director | Open-market purchase | common shares | 11,900 | $0.91 | $11K | |
| Richard Christopher - Officer | Open-market purchase | common shares | 15,000 | $0.91 | $14K | |
| John Martin Docherty - Officer | Open-market purchase | common shares | 5,376 | $0.93 | $5K | |
| William Edward McKechnie - Director | Open-market purchase | common shares | 5,000 | $0.91 | $5K | |
| Vanessa Carle - Officer | Open-market purchase | common shares | 750 | $0.91 | $683 | |
| Richard Christopher - Officer | Grant or award | Stock Options | 150,000 | $0.00 | - | |
| Albert L. Reese Jr. - Director | Grant or award | Stock Options | 11,000 | $0.00 | - | |
| Christopher Bunka - Director | Grant or award | Stock Options | 11,000 | $0.00 | - | |
| Richard Christopher - Officer | Open-market purchase | common shares | 22,828 | $2.24 | $51K | |
| Richard Christopher - Officer | Open-market purchase | common shares | 27,172 | $2.47 | $67K | |
LEXX insider trading FAQ
What is the latest insider trade for LEXX?
Lexaria Bioscience Corp. (LEXX) has filed no insider reports in the last 90 days. The most recent on record is dated 18 March 2026. The full record for LEXX runs to 10 Form 4 filings, the earliest from 3 December 2024. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying LEXX stock?
No insider purchases of LEXX were filed in the last 90 days. 8 purchases are on record for this company.
How many insiders are selling LEXX stock?
No insider sales of LEXX were filed in the last 90 days.
Where can I see LEXX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects LEXX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Christopher Bunka view on EDGAR
- - Christopher Bunka view on EDGAR
- - Richard Christopher view on EDGAR
- - John Martin Docherty view on EDGAR
- - William Edward McKechnie view on EDGAR
- - Vanessa Carle view on EDGAR
- - Richard Christopher view on EDGAR
- - Albert L. Reese Jr. view on EDGAR
- - Christopher Bunka view on EDGAR
- - Richard Christopher
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where LEXX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow LEXX with a 7-day demo
- LEXX on your watchlist
- Every LEXX Form 4 filing on record
- Up to 3 months of LEXX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
